Finance

Beta
Lists
MAZE:NASDAQ
Maze Therapeutics Inc
$28.88
+1.58%
(+0.45) 1D
Jun 29, 3:33:42 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MAZE...
Open
$28.02
High
$29.27
Low
$27.80
Mkt. cap
1.61B
Avg. vol.
653.60K
Volume
505.43K
52-wk high
$53.65
52-wk low
$10.98
EPS
-$2.52
Shares outstanding
55.34M
No. of employees
141
Open
$28.02
High
$29.27
Low
$27.80
Mkt. cap
1.61B
Avg. vol.
653.60K
Volume
505.43K
52-wk high
$53.65
52-wk low
$10.98
EPS
-$2.52
Shares outstanding
55.34M
No. of employees
141
News stories
From sources across the web
About Maze Therapeutics Inc
CEO-
Employees141
Founded2017
HeadquartersSouth San Francisco, California, United States
SectorPharmaceutical industry
Websitemazetx.com
Analyst ratings
Based on 8 analysts giving stock ratings to MAZE in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for MAZE in the last 3 months.
Highest
Current $28.88
$110.00 (+280.89%)
Average
$70.00 (+142.38%)
Lowest
$48.00 (+66.20%)
Analyst
Recommendation
Action
Price target
Projected
Date
Salim Syed
Mizuho Securities
Buy
Maintained
$97.00
+235.9%
06/23/2026
Ananda Ghosh
H.C. Wainwright
Buy
Reiterated
$110.00
+280.9%
06/22/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$53.00
+83.5%
05/22/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$57.00
+97.4%
05/16/2026
Danielle Brill
Truist Financial
Buy
Maintained
-
-
05/14/2026
Sadia Rahman
Wells Fargo
Buy
Maintained
$55.00
+90.4%
05/13/2026
Laura Chico
Wedbush
Buy
Maintained
$48.00
+66.2%
05/13/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/12/2026
Julian Harrison
BTIG
Buy
Maintained
$46.00
+59.3%
03/25/2026
Martin Auster
Raymond James
Buy
Reiterated
$56.00
+93.9%
03/25/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$50.00
+73.1%
03/25/2026
Debjit Chattopadhyay
Guggenheim
Buy
Reiterated
$58.00
+100.8%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
20.00M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
28.11M
25.19M
27.57M
34.15M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.37M
7.78M
10.49M
12.40M
Operating expense
36.47M
32.96M
38.06M
46.55M
Total operating expenses
36.47M
32.96M
38.06M
46.55M
Operating income
-36.47M
-32.96M
-38.06M
-26.55M
Other non operating income
-
-
-
-
EBT including unusual items
-33.68M
-30.09M
-34.57M
-24.21M
EBT excluding unusual items
-33.68M
-30.09M
-34.57M
-24.21M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-33.68M
-30.09M
-34.57M
-24.21M
Net profit margin
-
-
-
-121.04%
Earnings per share
-0.77
-0.66
-0.65
-0.45
Interest and investment income
2.80M
2.88M
3.49M
3.21M
Interest expense
-
-
-
-866.00K
Net interest expenses
2.80M
2.88M
3.49M
2.34M
Depreciation and amortization charges
-
-
-
-
EBITDA
-35.82M
-32.39M
-37.56M
-26.11M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer